The following clinical trials are either active and enrolling, upcoming or pending. Contact information is also listed for patients interested in enrolling.
COPD
Titania
A Phase III, Multicenter, Randomized, Double – blind, Chronic –dosing, Parallel –group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations. Click here for inclusion/exclusion criteria.
Principal Investigator: Huimin Wu, MD
Core Clinical Research Staff:
Juvaria Anjum, RN
Brittany Karfonta
Pillar
A 52-week, randomized, double-blind, double-dummy, placebo- and active- controlled (Roflumilast, Daliresp® 500µg), parallel group, study to evaluate the efficacy and safety of two doses of CHF6001 DPI add-on to maintenance triple therapy in subjects with Chronic Obstructive Pulmonary Disease (COPD) and chronic bronchitis. Click here for inclusion/exclusion criteria.
Principal Investigator: Huimin Wu, MD
Core Clinical Research Staff:
Juvaria Anjum, RN
Brittany Karfonta
INTERSTITIAL LUNG DISEASE
ATYR 1923 C 005
Randomized, double-blind, placebo-controlled Proof-of-Conept (PoC) study to evaluate the efficacy, safety, and tolerability of efzofitimod in patients with Systemic Sclerosis (SSc)-related iterstitial Lung Disease (ILD) (SSc-ILD). Click here for inclusion/exclusion criteria
Principal Investigator: Jad Kebbe, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN
ILD PRO
Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype Prospective Outcomes (ILD-PRO). Click here for inclusion/exclusion criteria
Principal Investigator: Jad Kebbe, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN
Teton Study (RIN-PF-301)
Ph 3 evaluating inhaled treprostinil (Tyvaso) for the treatment of IPF, inhaled treprostinil (6 mcg/breath) administered four times daily. Click here for inclusion/exclusion criteria
Principal Investigator: Jad Kebbe, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN
Teton RIN-PF-302
(IRB committee 11/14/22 - Board 2 - April 2023 1st rollover patient. An open-label extension study of inhaled Treprostinal in Subjects wtih Idiopathic Pulmonary Fibrosis. Click here for inclusion/exclusion criteria
Principal Investigator: Jad Kebbe, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN
Genentech GB44496
A two-cohort, phase II, multicenter randomized, double-blind, parallel-group, placebo-controlled study evaluating the efficacy and safety of Vixarelimab compared with placebo in patients with idiopathi pulmonary fibrosis and in patients with systemic sclerosis-associated interstitial lung. Click here for inclusion/exclusion criteria
Principal Investigator: Jad Kebbe, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN
INSO18-055-003 (Insilico)
A phase 2a, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmaokinetics, and efficay of INSO18-066 administered orally to subjects with Idiopathic Pulmonary Fibrosis (IPF). This study is pending.
Principal Investigator: Jad Kebbe, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN
BMS-986278
A study to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis. This study is pending.
Principal Investigator: Jad Kebbe, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN
IFE-008 (Cumberland)
A randomized, double-bline, placebo-controlled phase II study with an open-label extension to determine the safety and efficacy of oral Ifetroban in patients with Idiopathic Pulmonary Fibrosis. This study is pending.
Principal Investigator: Jad Kebbe, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN
SAROIDOSIS
aTyr1923-C-004
A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous Ezofitimod in patients with pulmonary sarcoidosis. Click here for inclusion/exclusion criteria
Principal Investigator: Salim Daouk, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN
ARDS
DOMPE REP01222 (RESPIRATIO)
A phase II, proof-of-concept, randomized, double-blinded, placebo controlled, multicenter study to assess efficacy of Reparixin ass add-on therapy to standard of care in adult patients with ARDS (Acute Repiratory Distress Syndrome. Click here for inclusions/exclusions criteria
Principal Investigator: Tony Abdo, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN
PULMONARY HYPERTENSION
ROR-PH-301
A study evaluating the efficacy and safety of Ralinepag to improve treatment outcomes in PAH patient. (This study is pending.)
Principal Investigator: Himanshu Bhardwaj, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN
COUGH
CALM 1
A phase 3, 52-week, randomized, double-blind, placebo-controlled, parallel-arm efficacy and safety study with open label extension of BLU-5937 in adult partiipants with refratory chronic cough, including unexplained chronic cough. Click here for inclusion/exclusion criteria
Principal Investigator: Adam Przebinda, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN
CATHETER-RELATED CLABSI
Mino-Lok
A Phase 3, Multi-Center, Randomized, Open-Label, Assessor-Blind Study to Evaluate the Efficacy and Safety of Mino-Lok Therapy (MLT) in Combination with Systemic Antibiotics in the Treatment of Catheter-Related or Central Line-Associated Bloodstream Infection
Principal Investigator: Houssein Youness, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN
COMMUNITY-ACQUIRED PNEUMONIA
DOMPE REP0312 (REPAVID)
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalized adult patients with community-acquired pneumonia. A multinational, multicenter, randomized, double-blinded, placebo-controlled, parallel-group phase III trial. Click here for inclusion/exclusion criteria
Principal Investigator: Houssein Youness, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN
Biotest 996 ESsCAPE
A randomized, placebo-controlled, double-blind, multicenter, phase III trial to asess the efficacy and safety of Trimodulin (BT588) in adult hospitalized subjects with severe community-acquired pneumonia (sCAP). Click here for inclusion/exclusion criteria
Principal Investigator: Houssein Youness, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN
SEPSIS
VasoActive Therapy
To evaluate the impact of the vasoactive therapy upon patients with sepsis by following routinely monitored parameters of inflammation and organ failures scores to evaluate vasoactive therapy's efficacy in mitigating the impact of sepsis on the human body. (This study is pending.)
Principal Investigator: Brent Brown, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN